The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172
- PMID: 1716140
- PMCID: PMC1368488
- DOI: 10.1111/j.1365-2125.1991.tb05608.x
The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172
Abstract
1. We have investigated the effect of repeated s.c. Org 10172 (a low molecular weight heparinoid; Lomoparan) treatment (1000 anti-Xa units twice daily for 5 days) on antipyrine (500 mg orally) metabolism, and the effect of enzyme induction by pentobarbitone (100 mg for 12 days) on the pharmacokinetics and pharmacodynamics of Org 10172 following an intravenous bolus injection of 3250 anti-Xa units. 2. Org 10172 treatment caused a small increase in the formation rates of all antipyrine metabolites (P less than 0.05), while the overall kinetics of antipyrine did not change significantly. 3. Oxidative enzyme induction by pentobarbitone, as demonstrated by an increased clearance of antipyrine, was associated with an increase in the area under the anti-thrombin activity vs time curve (P less than 0.05). No influence was seen on the kinetics of plasma anti-Xa and thrombin generation inhibiting (TGI) activity. 4. The pharmacodynamics of Org 10172, as determined by clotting tests, was not influenced by enzyme induction. 5. The clinical relevance of these observations is likely to be limited.
Similar articles
-
Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.J Clin Pharmacol. 1991 Jul;31(7):611-7. doi: 10.1002/j.1552-4604.1991.tb03746.x. J Clin Pharmacol. 1991. PMID: 1716644 Clinical Trial.
-
Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.Eur J Clin Pharmacol. 1991;41(3):245-50. doi: 10.1007/BF00315437. Eur J Clin Pharmacol. 1991. PMID: 1748141 Clinical Trial.
-
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.Br J Clin Pharmacol. 1987 Jun;23(6):667-75. doi: 10.1111/j.1365-2125.1987.tb03100.x. Br J Clin Pharmacol. 1987. PMID: 3606928 Free PMC article. Clinical Trial.
-
Pharmacokinetic considerations on Orgaran (Org 10172) therapy.Haemostasis. 1992;22(2):73-84. doi: 10.1159/000216298. Haemostasis. 1992. PMID: 1379967 Review.
-
Orgaran (Org 10172): its pharmacological profile in experimental models.Haemostasis. 1992;22(2):58-65. doi: 10.1159/000216296. Haemostasis. 1992. PMID: 1379965 Review.
Cited by
-
Danaparoid: a review of its use in thromboembolic and coagulation disorders.Drugs. 2002;62(15):2283-314. doi: 10.2165/00003495-200262150-00016. Drugs. 2002. PMID: 12381232 Review.
-
Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.Drugs. 1997 Dec;54(6):903-24. doi: 10.2165/00003495-199754060-00008. Drugs. 1997. PMID: 9421696 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources